Researchers simulated nearly every molecule in a bacterial cell — and then watched the cell grow and reproduce.

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Note: This project is more-or-less very experimental and does not have no-where near complete support for the Tiny BASIC language. I.e., it's tokenisation process is very basic and not suitable for ...

Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...